This page lists FDA-approved DMTs: Indications, Dosing, Route of Administration, and Pregnancy Rating.
*Relapsing forms include relapsing-remitting MS (RRMS), secondary-progressive MS (SPMS), and progressive-relapsing MS (PRMS), in those patients who continue to have relapses.
Zinbryta (daclizumab) was withdrawn from the worldwide market on March 2, 2018. Please see important information about the withdrawal in our Society News.
Indications: Adult patients with relapsing forms of MS*
Dosing: 150 mgs once a month
Route of Administration: subcutaneous injection
Pregnancy Category: None – due to the change in FDA reporting of pregnancy/lactation data